Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.
Important: Compounded GLP-1 medications discussed in this article are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational and informational purposes only. All prescription decisions are made by licensed healthcare providers. Consult your provider before starting any prescription medication.
One of the most common questions prospective patients ask about GLP-1 telehealth programs right now is whether the oral format actually works — and whether it's worth choosing over an injectable. MadeMed offers both, starting at $99 per month for oral semaglutide and also offering injectable semaglutide and both oral and injectable tirzepatide. This article breaks down what the research actually supports, what “oral semaglutide” means in the telehealth context, and how to think about the format decision from an evidence standpoint.
What “Oral Semaglutide” Actually Means in 2026
The term “oral GLP-1” covers at least four meaningfully different things in the current market, and conflating them produces bad decisions. Understanding the distinctions is the most important thing this article can offer.
FDA-approved oral semaglutide includes two products: Rybelsus, a daily swallowed tablet approved for type 2 diabetes management, and the oral Wegovy formulation that launched in late 2025 for weight management. Both have completed phase 3 clinical trial programs evaluating their efficacy, safety, and pharmacokinetics as finished drug products. They require specific administration conditions — typically an empty stomach, small amount of water, and a waiting period before eating — because oral bioavailability of semaglutide is inherently challenging due to its peptide structure and susceptibility to gastric degradation.
Compounded sublingual semaglutide — the format available through MadeMed and most other GLP-1 telehealth platforms — is a separate category. These are compounding pharmacy formulations that dissolve under the tongue rather than being swallowed. The mechanism bypasses initial gastric transit by relying on sublingual absorption through the mucous membranes. This is a pharmacologically coherent delivery route. However, compounded sublingual semaglutide has not been evaluated in equivalent phase 3 human clinical trials. The bioavailability, pharmacokinetic profile, and clinical outcomes of these formulations cannot be assumed to match those of either FDA-approved injectable semaglutide or FDA-approved oral semaglutide based on preclinical or theoretical arguments alone.
This isn't a reason to dismiss the format — it's a reason to understand what you're actually choosing. For a detailed review of how MadeMed structures its programs across all GLP-1 formats, see our full MadeMed platform review.
What the Injectable Evidence Base Establishes
Injectable semaglutide has the strongest and most established evidence base of any semaglutide formulation. The STEP trial program, published in peer-reviewed literature including the New England Journal of Medicine, studied once-weekly subcutaneous semaglutide at 2.4mg in adults with obesity combined with lifestyle intervention. The STEP 1 trial found clinically meaningful average body weight reduction in the treatment group versus placebo after 68 weeks. These are the trials that established the clinical rationale for GLP-1 therapy in weight management — and they used injectable, FDA-approved branded semaglutide under controlled trial conditions.
Compounded injectable semaglutide — the format also available through MadeMed — uses the same active ingredient (semaglutide) administered the same way (subcutaneous injection), but is a compounded formulation rather than an FDA-approved finished drug. The pharmacological mechanism is the same, but the regulatory status, quality control standards, and evidence basis for the specific compounded formulation differ. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality control before they are dispensed.
The Oral Semaglutide Clinical Picture: What Phase 3 Data Shows for FDA-Approved Formats
The oral Wegovy clinical program (OASIS trials) evaluated swallowed oral semaglutide at 50mg once daily in adults with obesity. Published results demonstrated meaningful weight reduction compared to placebo, though average weight loss figures were somewhat lower than those observed in the injectable STEP trials. These results establish proof of concept for oral semaglutide as a clinically effective approach — but again, these are trials of an FDA-approved finished drug product, not of compounded sublingual tablets.
The mechanistic argument for sublingual absorption is that it bypasses the gastric degradation challenge that makes oral peptide delivery difficult. Whether compounded sublingual semaglutide achieves clinically meaningful systemic exposure in practice — and at what doses — is not established by published phase 3 human trial data as of this writing. This is a genuine evidence gap, not a disqualifying flaw. Clinicians prescribe medications through compounding when the individual patient's needs support it. But patients deserve to know that the “oral semaglutide” available through telehealth platforms is not the same product, and does not have the same evidence base, as the oral Wegovy pill that launched in late 2025.
How MadeMed's Oral Semaglutide Pricing Compares to the Market
At a published starting price of $99 per month, MadeMed's oral semaglutide sits at the lower end of the compounded telehealth market for this format. For context, oral semaglutide sublingual tablets from other platforms are priced higher: the SynergyRx oral dissolving tablet program starts at $299 per month for semaglutide per publicly available information, while programs reviewed on this site, including FuturHealth and Remote Pharmacy, structure their pricing differently, with injectable-focused programs in comparable ranges.
The key pricing consideration that every prospective patient should apply: compare total cost at maintenance dose, not starting price. GLP-1 programs titrate upward over months. The $99 entry point applies to the lowest starting dose of oral semaglutide — the dose at which most clinical protocols begin before gradually increasing. As dose increases, price increases. The monthly cost at a therapeutic maintenance dose will be higher than the published starting price. Verify the full pricing tier structure directly on mademed.com before enrolling.
For the FDA-approved oral alternative: Novo Nordisk has published self-pay pricing for oral Wegovy at $149 per month for certain dose tiers through its manufacturer direct program. For patients who qualify and prefer an FDA-approved finished drug, the price differential between compounded sublingual semaglutide and the approved oral pill has narrowed significantly in 2026. This is a conversation to have with your prescribing clinician — not a decision to make based on cost alone, since eligibility, insurance, and individual medical history all factor in.
How to Think About the Format Decision
The right format — oral or injectable — is a clinical decision, not a marketing decision. A few questions worth discussing with your provider: Do you have any medical reason to avoid subcutaneous injections? Does your state's prescribing regulations or the platform's clinical protocols affect which formats are available to you? Is there a compounded tirzepatide option worth considering if semaglutide isn't the right fit? Are you looking for an FDA-approved finished drug product specifically, or are you open to a compounded formulation under medical supervision?
MadeMed offers the flexibility of both formats across two GLP-1 molecules (semaglutide and tirzepatide), which is a genuine differentiator compared to platforms that offer only one format or one molecule. Whether that flexibility translates to better outcomes for any individual patient is a question for their licensed clinician. This topic connects to what we cover in MadeMed Tirzepatide Review 2026: Compounded GLP-1/GIP Therapy, Pricing, and What to Know.
Frequently Asked Questions
Is oral semaglutide as effective as injectable semaglutide?
FDA-approved oral semaglutide (Rybelsus and oral Wegovy) has been studied in clinical trials and demonstrates meaningful weight reduction, though phase 3 trial data generally shows somewhat less average weight loss compared to injectable semaglutide at equivalent doses. Compounded sublingual semaglutide tablets — the format available through most telehealth platforms — have not been evaluated in equivalent phase 3 human trials. The bioavailability and clinical outcomes of compounded sublingual formats cannot be assumed to be equivalent to either FDA-approved injectable or FDA-approved oral semaglutide products.
Why is MadeMed's oral semaglutide priced lower than competitors?
MadeMed's published starting price for oral semaglutide ($99/month at the lowest dose) positions it at the lower end of the compounded telehealth market. Pricing differences between telehealth platforms reflect differences in pharmacy sourcing, bundled services, dose tier structures, and membership models. Lower starting price does not always reflect lower total cost at maintenance dose. Prospective patients should compare total monthly cost at their expected therapeutic dose, not just entry-level pricing.
What is the difference between compounded sublingual semaglutide and oral Wegovy?
Oral Wegovy is an FDA-approved finished drug product that has completed phase 3 clinical trials evaluating its safety, efficacy, and bioavailability as a swallowed tablet. Compounded sublingual semaglutide — the format available through telehealth platforms including MadeMed — is a compounding pharmacy formulation that dissolves under the tongue. It uses semaglutide as an active ingredient but is not FDA-approved and has not been evaluated in equivalent human clinical trials. The two formats have different regulatory statuses and different evidence bases.
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.